HeartFlow CEO John Farquhar sold 22,562 shares worth ~$626,100 on July 10, 2026, as part of a pre-arranged Rule 10b5-1 trading plan established in September 2025. The sale represents only a 5% reduction in his direct holdings, and he retains 435,373 shares valued at $11.63 million, indicating aligned interests with shareholders. The transaction is not considered a red flag given its non-discretionary nature and the company's strong Q1 performance with 41% year-over-year revenue growth.

Heartflow, an AI-driven diagnostic platform, shows strong 40% revenue growth but faces reimbursement headwinds and remains unprofitable. Omeros is transitioning to commercial stage with its newly approved drug Yartemlea, posting early Q1 2026 revenue of $9.89 million. The article recommends Omeros as the safer bet for 2026 despite trading at a premium, citing its transition to profitability versus Heartflow's expected positive free cash flow not until 2028.

Ventripoint Diagnostics announced support for the newly formed Global Congenital Heart Disease Alliance (GCHDA), positioning its AI-powered VMS+ cardiac imaging platform to address a critical global healthcare gap. With 16 million people living with congenital heart disease and over 90% of children in lower-income countries lacking timely care, Ventripoint's vendor-agnostic technology delivers MRI-level accuracy from standard echocardiograms. The alliance will fund and place four VMS+ units, signaling commercial validation in a rapidly growing AI cardiology market projected to reach $14.2 billion by the mid-2030s.

Stanford University's Board of Trustees completely exited their HeartFlow position by selling 312,234 shares for $8.48 million in Q1 2026. Despite the exit, the article suggests this was a strategic decision to lock in gains rather than a sign of concern, as HeartFlow's business fundamentals remain strong with 40% YoY revenue growth. However, the company remains unprofitable with a net loss of $116.8 million in 2025.

Five companies—VentriPoint Diagnostics, HeartBeam, Heartflow, Hyperfine, and GE Healthcare Technologies—are advancing AI-enabled cardiac diagnostic platforms to address the global heart disease crisis. Recent developments include VentriPoint's partnership with First Light Health for remote Indigenous communities, HeartBeam's collaboration with Mount Sinai on AI-ECG algorithms, Heartflow's new clinical registry data, Hyperfine's breakthrough stroke detection results, and GE Healthcare's role in the EU's COMPASS cardiotoxicity initiative.

HeartFlow's chief medical officer Rogers Campbell sold 64,533 shares worth approximately $1.66 million on March 19, 2026, reducing his direct holdings by 72.8%. The sale appears routine and executed under a pre-arranged plan rather than signaling loss of confidence. HeartFlow reported strong 2025 revenue growth of 40% year-over-year to $176 million, with 2026 guidance of $218-222 million, though the company remains unprofitable.

HeartFlow director Jeffrey Lightcap purchased 40,000 shares worth $1.05 million on December 16, 2025, just after the stock hit a 52-week low of $25.38. While the company shows strong revenue growth of 41% year-over-year in Q3, it faces significant profitability challenges with net losses expanding to $50.9 million. The insider buy suggests confidence in the company's future, but the stock remains risky for investors given its recent IPO status and limited public company track record.

Heartflow presented late-breaking data at AHA 2025 demonstrating that total plaque volume can predict cardiovascular events with high accuracy, showing patients in the highest plaque volume stage have over 5x greater risk of major cardiovascular events.